Overview:

Tears in eyes has a substantial role in lubricating the inner process and protecting eyes from infections or any other foreign matters. Dry eye syndrome is a disease where the lubrication process gets hindered due to lack of tear inflow. The global dry eye syndrome market is all ready to achieve 6.6% CAGR during the forecast period of 2022 to 2030. Market Research Future (MRFR) identified several growth opportunities that could trigger a positive effect.

Geriatric population, diabetes, rheumatoid arthritis, are few of the diseases that can trigger Dry Eye Syndrome Market Size . Better technological installations and treatment measures can also smoothen up the growth path for the dry eye syndrome market. However, stringent norms regarding medicine manufacturing can deter the market growth.

Segmentation:

Type, diagnosis, treatment, distribution channel and end-user are segments in which the global dry eye syndrome market has been segmented by MRFR. This attempt would ensure better look into factors that can improve the market position.

Based on the type, the dry eye syndrome market comprises evaporative dry eye syndrome aqueous dry eye syndrome, and others.

Based on the diagnosis, the dry eye syndrome market comprises Schirmer test, eye exam, and others. The Schirmer test is gaining substantial acknowledgement.  

Based on the treatment, the dry eye syndrome market includes nutritional supplements, serum eye drops, lubricant eye drops, anti-inflammatory drugs segments, surgery, and others. The lubricant eye drops segment includes oily tear eye drops, ointments, preservative-free drops, and others. The anti-inflammatory drugs segment encompasses tetracyclines, corticosteroids, and others. The surgery segment has punctal occlusion, intense pulsed light therapy, and others under its purview.

Based on the distribution channel, the Dry Eye Treatment  consists online pharmacies, retail pharmacies, hospital pharmacies, and others. The retail pharmacies are doing good, however, the online pharmacies can gain more, if they clear stringent government policies.

Based on the end-users, the dry eye syndrome market includes hospitals, clinics, home care, and others.

Regional Analysis:

The Americas, Europe, Asia Pacific (APAC), and the Middle East & Africa (MEA) are segments that can be assessed to understand a proper functioning of the global dry eye syndrome market. This market segmentation includes a detailed study of various growth pockets, which can be taken into consideration to chart the progress route.

The Americas has significant market dominance and this is due to better diagnosis, infrastructural strength, high expenditure, and easy reimbursement policies. The presence of the US, and Canada are also expected to fetch in revenues. Cuba is also doing great in South America, along with Brazil and Argentina. The presence of several titans like Auven therapeutics, Johnson & Johnson Vision, Acadia Pharmaceutical, and others is also adding fuel to the market growth.

Europe has the second largest market and is getting benefitted from the high patient population. Healthcare sector in the region is quite robust and has a name for receiving remarkable funds from governments and private organizations. The APAC market is emerging as a market with high potential where India, China, Australia, and others are performing well. All these regions are expecting high CAGR during the forecast period.

Competitive Landscape:

Various pharmaceuticals are impacting the global dry eye syndrome market by improving the competition in the market with strategic inclusions of processes like merger, acquisition, collaboration, and other methods. The global market is also gaining from such prolific moves. MRFR listed a few in their global dry eye syndrome market report and profiled them to get a hand over latest trends that could impact the market in the future. These companies are Novartis AG (Switzerland), Allergan (Republic of Ireland), Valent Pharmaceuticals (Canada), Otsuka Pharmaceutical Co. Ltd. (Japan), Acadia Pharmaceutical (U.S.), Johnson and Johnson Vision (U.S.), I-Med Pharma Inc. (Canada), Allostera Pharma (Canada), AFT pharmaceuticals (New Zealand), Santen Pharmaceuticals Co. Ltd., (Japan), Auven therapeutics (U.S.), Novaliq GmBh (Germany), and others.

 In August 2019, results from phase 2 and 3 of the ribonucleic acid (siRNA) inhibitor tivanisiran delivered positive outcomes as a cure for dry eye syndrome. The test is getting done by researchers from Sylentis and it has been conducted in six countries. The result shows a stark improvement in the condition.

About Market Research Future:

At Market Research Future (MRFR), we enable our customers to unravel the complexity of various industries through our Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), & Consulting Services. MRFR team have supreme objective to provide the optimum quality market research and intelligence services to our clients.

Contact us:

Market Research Future (part of Wantstats Research and Media Private Limited),

99 Hudson Street, 5Th Floor,

New York, New York 10013

United States of America

+1 628 258 0071

Email: sales@marketresearchfuture.com